BofA analyst Tazeen Ahmad lowered the firm’s price target on Alnylam (ALNY) to $529 from $530 and keeps a Buy rating on the shares after the company announced preliminary Q4 and FY25 revenues. The firm, which now models FY26 Amvuttra revenues of $4.41B, which would be up 91% year-over-year, remains bullish on the large commercial opportunity for the TTR franchise.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target lowered to $530 from $535 at Truist
- Alnylam assumed with an Outperform at Oppenheimer
- Alnylam price target lowered to $491 from $525 at Bernstein
- Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns
- Alnylam to invest $250M to expand manufacturing facility in Massachusetts